AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 15347715
Drug: Hepatobiliary scintigraphy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatobiliary scintigraphy after UDCA treatment
Trial: 9539282
Drug: Continuous daily
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous daily oral equine conjugated estrogen 0.625 mg (group A, N=10)
Trial: 9539282
Drug: Daily transdermal
RxNorm normalized name: Deponit 0.2 MG/HR Daily Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily transdermal 17beta‐estradiol 50 microg (group B, N=9)
Trial: 2263919
Drug: Pulsed ultrasound
RxNorm normalized name: ULTRASOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulsed ultrasound (1:9, 0.5 watt/cm2 at 1 MHz, for 10 min) 3 days a week for 4 weeks, then twice weekly for 4 weeks, and once weekly for the following 4 weeks.
Trial: 2263919
Drug: Placebo-ultrasound (standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo-ultrasound (standard treatment with paste impregnated bandage and self-adhesive elastic bandage).
Trial: 23497350
Drug: medical nutrition
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: medical nutrition therapy + advice to consume at least two pieces of fruit a day (high‐fruit)
Trial: 23497350
Drug: medical nutrition
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: medical nutrition therapy + advice to consume no more than two pieces of fruit a day (low‐fruit)
Trial: 16948990
Drug: Magnesium sulfate
RxNorm normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Magnesium sulfate (1.5 g intravenous for 20 minutes)
Trial: 16948990
Drug: Placebo (intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (intravenous solution for 20 minutes)
Trial: 14613735
Drug: Pravastatin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin (40 mg/day) for 3 months
Trial: 10586340
Drug: Anastrozole 1
RxNorm normalized name: anastrozole 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anastrozole 1 mg once daily orally (n = 29)
Trial: 10586340
Drug: Formestane 250
RxNorm normalized name: formestane 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formestane 250 mg once every two weeks by intramuscular injection (n = 31)
Trial: 1657128
Drug: Single infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single infusion of MAb C23 (5 to 80 mg)
Trial: 1657128
Drug: Three infusions
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three infusions of MAb C23 (60, 20, and 20 mg at 1-week intervals)
Trial: 6961425
Drug: Pyridoxine (vitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyridoxine (vitamin B-6) treatment
Trial: 30442217
Drug: Group psychological
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group psychological treatment program (8 one-hour sessions, cognitive-behavioral approach)
Trial: 27122490
Drug: Intrauterine infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intrauterine infusion of 500 IU hCG (n=7)
Trial: 8225149
Drug: Captopril (25-50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (25-50 mg daily)
Trial: 3517926
Drug: Stanozolol 5
RxNorm normalized name: stanozolol 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stanozolol 5 mg twice daily for six months
Trial: 30348178
Drug: Caffeine ingestion
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeine ingestion (5 mg.kg-1)
Trial: 27996026
Drug: Public reporting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Public reporting of prescriptions
Trial: 25509236
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g intravenous (IV) paracetamol 20 min before the operation
Trial: 25509236
Drug: 1 cc
RxNorm normalized name: BD Needle SG 1 cc 27g 5/8"
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 cc normal saline (placebo) 20 min before the operation
Trial: 22938071
Drug: Conventional Language
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional Language Therapy (CLT)
Trial: 20712134
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation of betahistine (16 mg tablet)
Trial: 20712134
Drug: Reference formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference formulation of betahistine (16 mg tablet)
Trial: 12812866
Drug: Insulin levels
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin levels of 35 microU/ml
Trial: 12812866
Drug: Insulin levels
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin levels of 85 microU/ml
Trial: 12812866
Drug: Insulin levels
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin levels of 25 microU/ml
Trial: 10827410
Drug: 0.5 x
RxNorm normalized name: PAD,FOAM 0.5 X 18 X 72IN BIACARE #5302
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 x 10(6) IU/m(2) of rIFN‐gamma (low‐dose group)
Trial: 10827410
Drug: 1.5 x
RxNorm normalized name: lisocabtagene maraleucel 1.5 x 10exp6 to 70 x 10exp6 cell/mL INTRAVEN VIAL (EA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 x 10(6) IU/m(2) of rIFN‐gamma (high‐dose group)
Trial: 10827410
Drug: rIFN‐gamma therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rIFN‐gamma therapy (both dosages)
Trial: 22205315
Drug: Entrée portion
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Entrée portion sizes of 100, 160, 220, 280, 340, and 400 g
Trial: 18598831
Drug: Isotonic sodium
RxNorm normalized name: ISOTONIC SODIUM CHLORIDE SOLUTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotonic sodium chloride solution nasal irrigation
Trial: 6238829
Drug: mianserin 10
RxNorm normalized name: mianserin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mianserin 10 mg
Trial: 6238829
Drug: amitriptyline 10
RxNorm normalized name: amitriptyline 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: amitriptyline 10 mg
Trial: 8473720
Drug: amitriptyline 50
RxNorm normalized name: amitriptyline 50 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: amitriptyline 50 mg
Trial: 6238829
Drug: zimeldine 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: zimeldine 200 mg
Trial: 6238829
Drug: ethanol 1
RxNorm normalized name: ethanol 1 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ethanol 1 g/kg bodyweight
Trial: 29220609
Drug: SSF‐Assessment Group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SSF‐Assessment Group Therapy
Trial: 29220609
Drug: Usual Assessment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual Assessment Group Therapy
Trial: 29516964
Drug: Rendezvous therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rendezvous therapy (radiotherapy with local delivery of nimustine and oral temozolomide)
Trial: 29516964
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (radiotherapy with concomitant and adjuvant temozolomide)
Trial: 24647023
Drug: Metronidazole (10-day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronidazole (10-day course, oral)
Trial: 22017387
Drug: Complex anthroposophic
RxNorm normalized name: hesperidin complex
DrugBank: Citrus bioflavonoids (DB14586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complex anthroposophic remedy (Apis regina tota GL D4, Argentum metallicum D5, Ovaria bovis GL D4), 3 × 10 globuli daily for 12 weeks
Trial: 16245418
Drug: Fenspiride 160
RxNorm normalized name: fenspiride
DrugBank: Fenspiride (DB08979)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenspiride 160 mg/day for 6 months
Trial: 12476070
Drug: Massage therapy
RxNorm normalized name: CAMPHOR (SYNTHETIC) 30 g in 1 mL / MENTHOL 40 g in 1 mL TOPICAL OIL [CBDMEDIC MASSAGE THERAPY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Massage therapy for 14 days
Trial: 9829492
Drug: Intravenous iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous iron therapy (Ferric saccharate, 100 mg dose, administered postdialysis on five consecutive dialysis sessions for 2 weeks)
Trial: 9829492
Drug: Intravenous ascorbic
RxNorm normalized name: ascorbate
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous ascorbic acid therapy (300 mg dose, administered thrice a week for 8 weeks)
Trial: 9829492
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (Control I and Control II, haematocrit > 30%, no adjuvant therapy)
Trial: 2667926
Drug: Continuous basal-rate
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous basal-rate intravenous insulin infusion
Trial: 2667926
Drug: Single daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single daily injections of ultralente insulin
Trial: 2667926
Drug: Single daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single daily injections of lente insulin
Trial: 996681
Drug: 220 mg
RxNorm normalized name: urea 220 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 220 mg zinc sulphate
Trial: 996681
Drug: 10 ml
RxNorm normalized name: Vial Empty 10 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 ml bicitropeptide
Trial: 7014104
Drug: Amineptine (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amineptine (mean 180 mg, range 100-300 mg)
Trial: 7014104
Drug: Clomipramine (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clomipramine (mean 84 mg, range 50-150 mg)
Trial: 29356603
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg dexketoprofen trometamol (DKT)
Trial: 29356603
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg vitamin C (PLACEBO)
Trial: 27821382
Drug: Intravenous eculizumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous eculizumab (900 mg/day)
Trial: 22168326
Drug: 0.1% topical
RxNorm normalized name: Halog 0.1% Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1% topical adapalene gel for 4 weeks (Group A)
Trial: 22168326
Drug: 0.1% topical
RxNorm normalized name: Halog 0.1% Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1% topical adapalene gel and 600 mg oral faropenem for 2 weeks followed by 0.1% topical adapalene gel alone for 2 weeks (Group B)
Trial: 22168326
Drug: 0.1% topical
RxNorm normalized name: Halog 0.1% Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1% topical adapalene gel and 600 mg oral faropenem for 4 weeks (Group C)
Trial: 18842788
Drug: Micronutrient supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micronutrient supplementation (daily tablet containing 15 micronutrients at just above the recommended nutrient intake)
Trial: 8923125
Drug: Milnacipran (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milnacipran (50 mg twice a day)
Trial: 1679243
Drug: Lorazepam 2
RxNorm normalized name: lorazepam 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorazepam 2 mg (single oral dose)
Trial: 6415364
Drug: Hormone treatment
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormone treatment with 4 mg oestradiol
Trial: 6415364
Drug: Hormone treatment
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormone treatment with 2 mg oestradiol
Trial: 6415364
Drug: Hormone treatment
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormone treatment with 1 mg oestradiol
Trial: 6415364
Drug: Withdrawal of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Withdrawal of hormone treatment
Trial: 30320964
Drug: Belimumab 10
RxNorm normalized name: Belimumab
DrugBank: Belimumab (DB08879)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Belimumab 10 mg/kg every 28 days plus standard therapy
Trial: 26294070
Drug: Low-dose isoflavone
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose isoflavone aglycone (25 mg/day)
Trial: 17400850
Drug: Mifepristone 200
RxNorm normalized name: mifepristone 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mifepristone 200 mg orally and misoprostol 800 mcg vaginally administered simultaneously
Trial: 17400850
Drug: Mifepristone 200
RxNorm normalized name: mifepristone 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mifepristone 200 mg orally and misoprostol 800 mcg vaginally administered 24 hours apart
Trial: 12729424
Drug: Itraconazole (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Itraconazole (200 mg intravenously every 12 hours for 2 days followed by 200 mg intravenously every 24 hours or a 200‐mg oral solution every 12 hours)
Trial: 12729424
Drug: Fluconazole (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluconazole (400 mg intravenously or orally every 24 hours)
Trial: 8952557
Drug: Tetracycline (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tetracycline (20 mg/kg [maximum of 2 g] in 50 mL of normal saline)
Trial: 8952557
Drug: Bleomycin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bleomycin (1 U/kg [maximum of 60 U] in 50 mL of normal saline)
Trial: 8952557
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of tetracycline (20 mg/kg [maximum of 2 g] in 40 mL of normal saline) and bleomycin (1 U/kg [maximum of 60 U] in 30 mL of normal saline)
Trial: 7381634
Drug: Cloxacillin administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cloxacillin administered intravenously for ten days
Trial: 7381634
Drug: Carbenicillin plus
RxNorm normalized name: carbenicillin
DrugBank: Carbenicillin (DB00578)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carbenicillin plus gentamicin administered intravenously for ten days
Trial: 25320597
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of dexamethasone 8mg and ondansetron 4mg
Trial: 18762508
Drug: Oral sucrose
RxNorm normalized name: TootSweet 24% Oral Sucrose Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral sucrose solution (1 mL of 25% sucrose solution)
Trial: 15785924
Drug: Brimonidine 0.2%
RxNorm normalized name: BRIMONIDINE 0.2%/TIMOLOL 0.5% OPH SOLN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brimonidine 0.2% applied topically, twice a day for 4-48 hours before laser treatment and continued for 1 month.
Trial: 15785924
Drug: Placebo (matched
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (matched control group), applied topically, twice a day for 4-48 hours before laser treatment and continued for 1 month.
Trial: 7738792
Drug: Enoximone bolus
RxNorm normalized name: enoximone
DrugBank: Enoximone (DB04880)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoximone bolus single dose (0.25‐2.0 mg/kg)
Trial: 7738792
Drug: Enoximone continuous
RxNorm normalized name: enoximone
DrugBank: Enoximone (DB04880)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoximone continuous infusion (4‐h)
Trial: 7738792
Drug: Enoximone bolus
RxNorm normalized name: enoximone
DrugBank: Enoximone (DB04880)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoximone bolus multiple doses (four consecutive doses at 3‐h intervals)
Trial: 2028004
Drug: Nonionic (low‐osmolality)
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonionic (low‐osmolality) contrast agents
Trial: 6797454
Drug: MR 1268
RxNorm normalized name: verapamil hydrochloride Extended Release Oral Tablet [Ethimil MR]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MR 1268 2.5 mg
Trial: 6797454
Drug: MR 1268
RxNorm normalized name: verapamil hydrochloride Extended Release Oral Tablet [Ethimil MR]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MR 1268 5 mg
Trial: 6797454
Drug: MR 1268
RxNorm normalized name: verapamil hydrochloride Extended Release Oral Tablet [Ethimil MR]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MR 1268 10 mg
Trial: 6797454
Drug: MR 1268
RxNorm normalized name: verapamil hydrochloride Extended Release Oral Tablet [Ethimil MR]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MR 1268 20 mg
Trial: 28415943
Drug: 20 mL of
RxNorm normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mL of 0.5% bupivacaine (Group B, n = 30)
Trial: 28415943
Drug: 20 mL of
RxNorm normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mL of 0.5% levobupivacaine (Group L, n = 30)
Trial: 25903217
Drug: Intravenous alcohol
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous alcohol self-administration (up to a maximum BAC of 160 mg% in study 1 and 120 mg% in study 2)
Trial: 23574969
Drug: Etanercept (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etanercept (10 mg)
Trial: 16687482
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of physiotherapy and brace
Trial: 9165176
Drug: Moderate aerobic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate aerobic exercise added to medical antihypertensive therapy
Trial: 9165176
Drug: Medical antihypertensive
RxNorm normalized name: ANTIHYPERTENSIVES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical antihypertensive therapy (indapamide +/- verapamil +/- enalapril)
Trial: 21620416
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D3 as add-on therapy to subcutaneous interferon β-1a
Trial: 21620416
Drug: Placebo as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo as add-on therapy to subcutaneous interferon β-1a
Trial: 18980263
Drug: Caffeine (1.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (1.75 mg/kg) three times daily for four consecutive weeks
Trial: 14583369
Drug: Bisoprolol 5
RxNorm normalized name: bisoprolol 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bisoprolol 5 to 10 mg once daily
Trial: 14583369
Drug: Carvedilol 12.5
RxNorm normalized name: carvedilol 12.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carvedilol 12.5 to 25 mg twice daily
Trial: 8664034
Drug: Regimen B
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regimen B (daily oral treatment with 30 mg of TAM and 600 mg of FT)
Trial: 8664034
Drug: Regimen A
RxNorm normalized name: CHLOROXYLENOL 5 g in 1000 mL TOPICAL SOAP [REGIMEN ANTIMICROBIAL]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regimen A (daily oral treatment with 30 mg of TAM)
Trial: 8664034
Drug: Regimen C
RxNorm normalized name: ASPIRIN 81 mg ORAL TABLET, CHEWABLE [Bayer Aspirin Regimen Chewable Low Dose Aspirin Orange]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regimen C (daily oral treatment with 30 mg of TAM and 3 g of PSK)
Trial: 8664034
Drug: Regimen D
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regimen D (daily oral treatment with 600 mg of FT)
Trial: 8664034
Drug: Regimen E
RxNorm normalized name: ASPIRIN 325 mg ORAL TABLET, COATED [Bayer Aspirin Regimen enteric coated]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regimen E (daily oral treatment with 3 g of PSK)
Trial: 27555486
Drug: Interlaminar epidural
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interlaminar epidural steroid administration (Group S, n=48) with 10 mL 0.25% bupivacaine + 40 mg methylprednisolone.
Trial: 27555486
Drug: Interlaminar epidural
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interlaminar epidural local anesthetic administration (Group L, n=50) with 10 mL 0.25% bupivacaine.
Trial: 26602290
Drug: Lactoferrin‐fortified formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactoferrin‐fortified formula milk group (FG, containing lactoferrin 38 mg/100 g milk)
Trial: 24433430
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy (methotrexate/ciclosporin/prednisolone)
Trial: 24433430
Drug: Monotherapy (methotrexate)
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy (methotrexate)
Trial: 19056555
Drug: Control bar
RxNorm normalized name: SALICYLIC ACID 2 g in 100 g TOPICAL SOAP [Blemish Control Bar]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control bar containing 0.3 g beta-glucan from 6.8 g oats
Trial: 19056555
Drug: Bar with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bar with an additional 0.9 g beta-glucan from 8.0 g barley
Trial: 19056555
Drug: Bar with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bar with 8 g FOS
Trial: 19056555
Drug: Bar with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bar with 0.9 g beta-glucan + 8 g FOS